9-NITROCAMPTOTHECIN LIPOSOME AEROSOL: LACK OF SUBACUTE TOXICITY IN DOGS

9-Nitrocamptothecin (9-NC) dilauroylphosphatidylcholine (DLPC) liposome aerosol was evaluated for potential toxicity in an 8-wk, subacute toxicity study in dogs. Fourteen adult dogs were divided into 2 groups with 10 animals in the 9-NC-DLPC treatment group and 4 animals in the DLPC-only vehicle control group. 9-NC-DLPC was administered to the animals using an Aerotech II nebulizer flowing at 10 L/min. Fullface exposures for 60 min were conducted for 5 consecutive days a week for 8 wk. The estimated deposited aerosol dose was 24.7 µg/kg/day. Animals in the vehicle control group received aerosolized DLPC only. Body weight, food consumption, urinalysis, in-life observations, hematology, plasma chemistry, and necropsy and histopathology were monitored before and during the treatment period and in a subset of animals for 2 wk following the end of treatment. Animals were observed for signs of pharmacologic and/or toxicologic effects three times on days of dosing and once daily on nondosing days. 9-NC-DLPC liposomes administered as a small-particle aerosol were determined to be nontoxic to dogs when given for 5 days/wk, for a duration of 8 wk. DLPC-only liposome also had no toxic effects.

[1]  C. Verschraegen,et al.  Alternative Administration of Camptothecin Analogues , 2000, Annals of the New York Academy of Sciences.

[2]  E. Kleinerman,et al.  9‐Nitrocamptothecin Liposome Aerosol Treatment of Human Cancer Subcutaneous Xenografts and Pulmonary Cancer Metastases in Mice , 2000, Annals of the New York Academy of Sciences.

[3]  E. Kleinerman,et al.  9-Nitrocamptothecin liposome aerosol treatment of melanoma and osteosarcoma lung metastases in mice. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  B. Giovanella,et al.  A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. , 1999, International journal of oncology.

[5]  C. Verschraegen,et al.  A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer. , 1999, Anti-cancer drugs.

[6]  S. Hirota,et al.  Effective Irinotecan (CPT‐11)‐containing Liposomes: Intraliposomal Conversion to the Active Metabolite SN‐38 , 1999, Japanese journal of cancer research : Gann.

[7]  S. Arbuck,et al.  Clinical applications of the camptothecins. , 1998, Biochimica et biophysica acta.

[8]  C. Verschraegen,et al.  A phase I clinical and pharmacological study of oral 9-nitrocamptothecin, a novel water-insoluble topoisomerase I inhibitor , 1998, Anti-cancer drugs.

[9]  C. Nastruzzi,et al.  Formulation study for the antitumor drug camptothecin: liposomes, micellar solutions and a microemulsion , 1997 .

[10]  C. Verschraegen,et al.  Phase I Clinical and Pharmacological Studies of 20‐(S)‐Camptothecin and 20‐(S)‐9‐Nitrocamptothecin as Anticancer Agents , 1996, Annals of the New York Academy of Sciences.

[11]  B. Giovanella,et al.  Protocols for the Treatment of Human Tumor Xenografts with Camptothecins , 1996, Annals of the New York Academy of Sciences.

[12]  E. Eisenhauer,et al.  Current perspectives on camptothecins in cancer treatment. , 1996, British Journal of Cancer.

[13]  M. Wani,et al.  Camptothecin and taxol: discovery to clinic--thirteenth Bruce F. Cain Memorial Award Lecture. , 1995, Cancer research.

[14]  D. Kufe,et al.  Partial characterization of human leukemia U‐937 cell sublines resistant to 9‐nitrocamptothecin P , 1994, European journal of haematology.

[15]  X. Gao,et al.  Stabilization of topotecan in low pH liposomes composed of distearoylphosphatidylcholine. , 1994, Journal of pharmaceutical sciences.

[16]  V. Knight,et al.  CHARACTERIZATION AND ADMINISTRATION OF CYCLOSPORINE LIPOSOMES AS A SMALL‐PARTICLE AEROSOL , 1993, Transplantation.

[17]  T. Burke,et al.  Lipid bilayer partitioning and stability of camptothecin drugs. , 1993, Biochemistry.

[18]  P. Pantazis,et al.  Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non‐tumorigenic and tumorigenic cells in vitro , 1993, International journal of cancer.

[19]  K. Kohn,et al.  Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. , 1989, Cancer research.

[20]  M. Wani,et al.  Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogues. , 1986, Journal of medicinal chemistry.

[21]  B. Giovanella,et al.  Anticancer exffect of 9-nitrocamptothecin liposome aerosol on human cancer xenografts in nude mice , 1999, Cancer Chemotherapy and Pharmacology.

[22]  J. Waldrep,et al.  Distribution of camptothecin after delivery as a liposome aerosol or following intramuscular injection in mice , 1999, Cancer Chemotherapy and Pharmacology.

[23]  J. Waldrep,et al.  CYCLOSPORIN A LIPOSOME AEROSOL: LAC K OF ACUTE TOXICITY IN RATS WITH A HIGH INCIDENCE OF UNDERLYING PNEUMONITIS , 1997 .

[24]  P. Pantazis,et al.  Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts. , 1993, Oncology research.